MAP2K7 and melanoma: In connection with these findings, we also observed similar upregulation of OXPHOS and increased sensitivity to SR4 or niclosamide of melanoma cells chronically treated with the MEK inhibitor trametinib or with the vemurafenib/trametinib combination (data not shown).